Chairman of the board at Coloplast Lars Rasmussen says he's had bad experiences with giving the public an insight into tax payments across the world, in an interview with Danish business daily Børsen.
On the one hand, it is good that the medtech company has publicized its tax payments for EU member states prior to the upcoming directive that would make this a requirement, the Coloplast's chair says. On the other, the same information on a global scale is a complicated issue that isn't easy to communicate clearly, he says.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.